CL2023001991A1 - Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo - Google Patents
Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismoInfo
- Publication number
- CL2023001991A1 CL2023001991A1 CL2023001991A CL2023001991A CL2023001991A1 CL 2023001991 A1 CL2023001991 A1 CL 2023001991A1 CL 2023001991 A CL2023001991 A CL 2023001991A CL 2023001991 A CL2023001991 A CL 2023001991A CL 2023001991 A1 CL2023001991 A1 CL 2023001991A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- activation protein
- protein ligand
- fibroblast activation
- xaa1
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title 1
- 210000002950 fibroblast Anatomy 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 108010069514 Cyclic Peptides Proteins 0.000 abstract 1
- 102000001189 Cyclic Peptides Human genes 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 238000011191 terminal modification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14001—Dipeptidyl-peptidase I (3.4.14.1), i.e. cathepsin-C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Optics & Photonics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un compuesto que comprende un péptido cíclico de la fórmula (I) y un grupo A de modificación de N-terminal sujeto a Xaa1 en donde cada uno de Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 y Xaa7 es un residuo de un aminoácido, y Yc es una estructura de fórmula (X)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163134704P | 2021-01-07 | 2021-01-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023001991A1 true CL2023001991A1 (es) | 2023-12-15 |
Family
ID=80050672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023001991A CL2023001991A1 (es) | 2021-01-07 | 2023-07-06 | Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230212549A1 (es) |
EP (1) | EP4274835A1 (es) |
JP (1) | JP2024503637A (es) |
KR (1) | KR20230129261A (es) |
CN (1) | CN116940585A (es) |
AU (1) | AU2022205523A1 (es) |
CA (1) | CA3206863A1 (es) |
CL (1) | CL2023001991A1 (es) |
IL (1) | IL303925A (es) |
MX (1) | MX2023007869A (es) |
WO (1) | WO2022148843A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023152671A1 (en) | 2022-02-09 | 2023-08-17 | Novartis Ag | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
NZ503359A (en) | 1997-09-29 | 2002-02-01 | Point Therapeutics Inc | Method for proliferating haematopoietic cells in vitro in the absence of exogenous cytokines |
EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
AU2001256325A1 (en) | 2000-03-17 | 2001-09-24 | Boehringer Ingelheim Pharma Kg | Human and humanized fap-alpha-specific antibodies |
US7374898B2 (en) | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
WO2006125227A2 (en) | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
JP2010523477A (ja) | 2007-03-20 | 2010-07-15 | トラスティーズ オブ タフツ カレッジ | 線維芽細胞活性化タンパク質の阻害剤、およびそれを使用する方法 |
WO2010036814A1 (en) | 2008-09-25 | 2010-04-01 | Molecular Insight Pharmaceuticals, Inc. | Selective seprase inhibitors |
WO2011040972A1 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
BR112013003361B8 (pt) | 2010-08-13 | 2022-01-25 | Roche Glycart Ag | Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo |
WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
WO2016146174A1 (en) | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
CN109689115A (zh) | 2016-06-10 | 2019-04-26 | 拜耳制药股份公司 | 放射性药物配合物 |
JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
EA202090776A1 (ru) | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
EP3763726A1 (en) * | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
-
2022
- 2022-01-07 MX MX2023007869A patent/MX2023007869A/es unknown
- 2022-01-07 KR KR1020237026404A patent/KR20230129261A/ko unknown
- 2022-01-07 WO PCT/EP2022/050280 patent/WO2022148843A1/en active Application Filing
- 2022-01-07 CA CA3206863A patent/CA3206863A1/en active Pending
- 2022-01-07 US US17/571,067 patent/US20230212549A1/en active Pending
- 2022-01-07 JP JP2023541264A patent/JP2024503637A/ja active Pending
- 2022-01-07 EP EP22700892.7A patent/EP4274835A1/en active Pending
- 2022-01-07 CN CN202280019456.5A patent/CN116940585A/zh active Pending
- 2022-01-07 AU AU2022205523A patent/AU2022205523A1/en active Pending
- 2022-01-07 IL IL303925A patent/IL303925A/en unknown
-
2023
- 2023-07-06 CL CL2023001991A patent/CL2023001991A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN116940585A (zh) | 2023-10-24 |
JP2024503637A (ja) | 2024-01-26 |
MX2023007869A (es) | 2023-09-22 |
CA3206863A1 (en) | 2022-07-14 |
WO2022148843A1 (en) | 2022-07-14 |
US20230212549A1 (en) | 2023-07-06 |
KR20230129261A (ko) | 2023-09-07 |
AU2022205523A1 (en) | 2023-07-13 |
IL303925A (en) | 2023-08-01 |
EP4274835A1 (en) | 2023-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000016A1 (es) | Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo | |
CL2023001991A1 (es) | Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo | |
RU2012147267A (ru) | Эффективные аналоги компстатина | |
PE20091753A1 (es) | Conjugados antagonistas peptidicos analogos a la bombesina | |
Hook et al. | The Proteolytic Stability of ‘Designed’β‐Peptides Containing α‐Peptide‐Bond Mimics and of Mixed α, β‐Peptides: Application to the Construction of MHC‐Binding Peptides | |
Shannon et al. | Sulfonyl fluoride analogues as activity‐based probes for serine proteases | |
ATE540054T1 (de) | Antimikrobielle theta defensine und verfahren zu deren verwendung | |
ES2585580T3 (es) | Péptidos novedosos antienvejecimiento y composición cosmética y/o farmacéutica que los contiene | |
CA2697518A1 (en) | A feeder cell-free culture medium and system | |
CO6150201A2 (es) | Anticuerpo humanizado contra beta amiloide | |
BR112022000122A2 (pt) | Compostos que compreendem um ligante de proteína de ativação de fibroblasto e uso dos mesmos | |
JP6142038B2 (ja) | 多能性幹細胞の培養方法及びこれに用いるポリペプチド | |
JP2019123717A (ja) | ベータ−ヘアピンペプチド模倣体 | |
JP2019116489A (ja) | ベータ−ヘアピンペプチド模倣体 | |
ES2607490T3 (es) | Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen | |
CN105874058A (zh) | 多肽组合物及使用其的多能干细胞的培养方法 | |
AU2013277637C1 (en) | Synthesis of beta-turn peptidomimetic cyclic compounds | |
RU2013145467A (ru) | Композиции для предупреждения и/или лечения инфекции, вызванной вирусом вич-1 | |
AU2016235590A1 (en) | Beta-hairpin peptidomimetics | |
US20180208902A1 (en) | Method for culturing pluripotent stem cells, method for manufacturing culture vessel, culture vessel, and scaffold material for culturing cells | |
CN105683371A (zh) | 用于稳定凝血酶活性的化合物和方法 | |
BR112015018283A2 (pt) | Composto peptídico agonista e composição farmacêutica ou veterinária | |
CN112062828B (zh) | Fgf-5多肽抑制剂及其生发应用 | |
ATE465172T1 (de) | Peptidträger für die verabreichung von arzneimitteln | |
US10259847B2 (en) | Beta-hairpin peptidomimetics |